top of page
Nominated for Best
Biotech Start Up 2024

First-in-Class Cancer Therapies.
Transforming Tomorrow's Care Today.

Our Story

At Ymmunobio, our research is based on our deep understanding of precision cancer treatments. We leverage our profound knowledge of biology, focusing on unique and first-in-class targets while selecting the optimal approach to developing transformative therapeutics across cancer indications.

Ymmunobio is committed to developing preclinical breakthroughs toward improving how cancer therapies are developed.
Dr. Katrin Rupalla & Dr. Peter Schiemann co-founded Ymmunobio in 2021 as a way to advance developments solid tumor research. Since that time, Ymmunobio has assembled a distinguished team of scientific and clinical leaders who are united in transforming how cancer and autoimmune diseases are treated.

Check out our latest LinkedIn posts 

bottom of page